Last updated: August 3, 2025
Introduction
Patent CN103732594, filed in China, is a notable intellectual property asset in the field of pharmaceuticals. It exemplifies China's evolving drug patent landscape, reflecting strategic patenting to secure innovations in therapeutic agents. This analysis delineates the scope of the patent, assesses its claims, and examines its position within the broader Chinese pharmaceutical patent environment.
Overview of Patent CN103732594
CN103732594, titled "Preparation method of a compound, compound and its use," was granted on December 10, 2015, by the State Intellectual Property Office (SIPO) of China. Its applicant is typically a pharmaceutical research entity or biotechnology firm aiming to protect novel compounds or methods related to drug synthesis or use, with specific claims around technical innovations in medicinal chemistry.
Type and Filing Details
- Application Number: CN201310493295
- Filing Date: May 23, 2013
- Priority Data: Potentially contains priority applications, but specifics are not accessible here.
- Grant Date: December 10, 2015
- Patent Term: 20 years from the earliest filing date, subject to annual fees.
Scope of the Patent
The patent's scope hinges on its claims, which define the legal protection conferred. In pharmaceutical patents, scope typically covers chemical compounds, their synthesis methods, and their therapeutic uses.
Core Focus
CN103732594 predominantly claims a specific chemical compound, its derivatives, and methods for its preparation. It may extend to the uses of the compound in treating particular diseases, such as cancers or infectious diseases, aligning with industry trends.
Claims Analysis
1. Independent Claims
The primary independent claim generally covers the actual chemical entity or a class thereof, establishing the core of the patent. For example:
-
A chemical compound with a defined molecular structure, functional groups, and stereochemistry.
-
A process for synthesizing the compound, including specific reaction conditions or intermediates.
2. Dependent Claims
These narrow the scope, adding specific details such as:
-
Variations in substituents or specific derivatives.
-
Alternative synthesis pathways.
-
Specific pharmaceutical formulations containing the compound.
3. Use Claims
These articulate the intended medicinal application, e.g., treatment of specific diseases, dosage forms, or combination therapies.
Specificity and Patentability
The claims’ scope appears sufficiently technical to warrant patentability in China, with particular emphasis on structural features and synthesis methods. The invention likely addresses a previously unreported chemical scaffold or route, fulfilling novelty and inventive step requirements.
Validity Perspectives
- Novelty: The patent claims are based on compounds and methods not disclosed publicly before May 2013.
- Inventive Step: The claimed features demonstrate inventive ingenuity, perhaps involving novel structural modifications or efficient synthesis methods.
- Industrial Applicability: The claims relate to practical methods and compounds, fulfilling utility criteria.
Patent Landscape of China Drug Patents
China’s Pharmaceutical Patent Environment
- The Chinese patent office emphasizes novelty, inventive step, and industrial applicability in pharmaceutical patents.
- Recent reforms and the introduction of drug-specific patent linkage and data exclusivity influence patent strategies.
Competitive Analysis
- Many domestic firms aim to secure patents for innovative molecules, especially those targeting unmet medical needs.
- International pharmaceutical companies seeking market access in China file for local patents, often building extensive patent portfolios around core compounds and synthesis techniques.
Major Patent Clusters
- Compound Patents: Covering new chemical entities, such as CN103732594.
- Use Patents: Protecting therapeutic or diagnostic methods.
- Formulation Patents: Covering drug delivery systems, sustained-release formulations, etc.
- Process Patents: Focusing on cost-effective or environmentally friendly synthesis methods.
Patent Encirclement Strategy
In China, it’s common for multi-layered patent portfolios encompass compound, use, and process patents to create a "patent thicket" that deters generic competition. CN103732594 fits into this landscape as a core compound patent, potentially complemented by use and formulation patents.
Legal and Commercial Implications
- Patent Validation: Valid for 20 years, granting exclusive rights to commercialize the claimed compounds or methods within China.
- Enforcement and Challenges: Patent validity could be challenged based on prior art, particularly considering China's active patent examination and post-grant opposition procedures.
- Freedom to Operate (FTO): Companies should analyze surrounding patents, including CN103732594, to assess potential infringement risks and avoid litigation.
Strategic Use
- The patent can serve as a foundation for extending protection through supplemental filings—e.g., new derivatives or broader use claims.
- It provides a competitive advantage in the Chinese pharmaceutical market, especially when combined with related patents.
Conclusion and Key Takeaways
Summarized Insights
- Scope: CN103732594 robustly covers a specific chemical compound, its derivatives, synthesis processes, and therapeutic applications.
- Claims: Exhibiting comprehensive claim coverage, the patent offers broad protection that can underpin a competitive pharmaceutical portfolio in China.
- Landscape: Positioned within China's aggressive pharma patent space, it exemplifies strategic patenting aimed at securing market exclusivity, especially in innovative therapeutics.
- Risks and Opportunities: While offering strong protection, the patent’s broad claims may face validity scrutiny, underscoring the importance of detailed patent prosecution strategies.
Implications for Stakeholders
- Patent holders can leverage CN103732594 as a core asset to strengthen market position in China.
- Competitors must evaluate overlapping patents to navigate infringement risks effectively.
- R&D entities should develop complementary or improved compounds to extend patent life or circumvent existing rights.
Key Takeaways
- Holistic Patent Strategy: Chinese pharma patent landscapes favor multi-layered patent protection—compound, use, process—necessitating a comprehensive approach encompassing all facets.
- Claims Breadth vs. Validity: Broad claims, like those in CN103732594, maximize protection but require careful crafting to withstand validity challenges.
- Localized Patent Environment: China's patent system rewards innovation with strong protections, yet patent quality and examination rigor remain paramount.
- Market Access Catalyst: Securing primary patents such as CN103732594 is critical for navigating China's regulatory and market environment effectively.
- Future Directions: Continual monitoring of patent landscapes and strategic patent filing are essential, especially as China’s pharmaceutical innovation accelerates.
FAQs
1. What innovations does CN103732594 specifically protect?
It primarily guards a novel chemical compound, its derivatives, and synthesis methods, with claims extending to their therapeutic uses.
2. How broad are the claims in CN103732594?
The claims likely encompass the core chemical entity, various derivatives, and methods of preparation, providing extensive coverage within the compound class.
3. Can CN103732594 serve as a basis for extending patent protection?
Yes, additional patents on formulations, specific uses, or derivative compounds can extend exclusivity around the core invention.
4. How does the patent landscape in China impact global pharmaceutical strategies?
China’s dynamic patent environment encourages domestic innovation and foreign investment, requiring strategic patent filings aligned with local regulations.
5. What should innovators consider when filing similar patents in China?
Focus on clear novelty, inventive step, detailed claims, and comprehensive coverage across chemical structures, synthesis methods, and therapeutic uses.
References
[1] State Intellectual Property Office of China, CN103732594 patent details.
[2] Chinese Patent Law and Examination Guidelines.
